In patients with kidney cancer, the three types of drugs that accounted for 100% of the expenditure included tyrosine kinase inhibitors (65.65%), immunotherapy (26.24%), and the mTOR inhibitor temsirolimus (8.11%). This evidence concerns the gene MTOR and kidney cancer.